11-19-61

Certificate of Mailing

Date of Deposit November 16, 2001	<u>Label Number: EL509047397US</u>
-----------------------------------	------------------------------------

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231

Guy Beardsley

Printed name of person mailing correspondence

Sequence Listing on Paper

Preliminary Amendment

Sequence Listing on Diskette

Small Entity Statement, which is:

□ A copy from prior application [**SERIAL NUMBER**] and

such small entity status is still proper and desired.

Signature of person mailing correspondence

15 pages

[**] pages

[**] pages

1 disk

UTILITY PATENT	APPLICATION TRANSMITTA	L UNDER 37 C.F.R. § 1.53(b)	
Attorney Docket Number	00742/066002		
Applicant	Thomas L. Benjamin, et a	Thomas L. Benjamin, et al.	
Title	DIAGNOSING AN TREAT	DIAGNOSING AN TREATING CANCER CELLS USING Sal2	
PRIORITY INFORMATION:			
09/812.633, filed March 19, 20	01, and claims priority from U.S	from United States patent application S. Provisional Application Number e hereby included by reference.	
SMALL ENTITY STATUS:			
■ Applicant claims small entity	status under 37 C.F.R. § 1.27		
APPLICATION ELEMENTS:			
Cover sheet		1 page	
Specification		50 pages	
Claims		2 pages	
Abstract		1 pages	
Drawing		11 sheets	
Combined Declaration and PC ■ Unsigned; □ Newly signed for this application □ A copy from prior application the entire disclosure of the prior being part of the disclosure of hereby incorporated by referen	ation; n [**SERIAL NUMBER**] and or application is considered as this new application and is	3 pages	
Sequence Statement		2 pages	



IDS	[**] pages
Form PTO 1449	[**] pages
Cited References	[**] references
Recordation Form Cover Sheet and Assignment	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$370	\$370.00
Excess Claims Fee: 10 - 20 x \$9	\$***
Excess Independent Claims Fee: 3 - 3 x \$42	\$***
Multiple Dependent Claims Fee: \$140	\$***
Total Fees:	\$370.00

- ☐ Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees.
- ☐ The filing fee is not being paid at this time.
- Please apply any other charges, or any credits, to Deposit Account No. 03-2095.

CORRESPONDENCE ADDRESS:

Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109 Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Date

CUSTOMER NO: 21559

Signature/

É:\00742\00742.066002 CIP Transmittal Form.wpd



21559 PATENT_TRADEMARK OFFICE Certificate of Mailing:

Date of Deposit: November 16, 2001

Label Number: EL509047397US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Guv Beardsley

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Thomas L. Benjamin, et al.

Art Unit:

Serial No.:

Examiner:

Filed:

November 16, 2001

Customer No.:

21559

Title:

DIAGNOSING AND TREATING CANCER CELLS USING SAL2

BOX PATENT APPLICATION

Assistant Commissioner For Patents

Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 15 pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney.

Each sequence in the application appears separately in the sequence listing, and each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout

the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: <u>November 16, 200</u>1

Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109

Susan M. Michaud Reg. No. 42,885

M. Michaud

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

F:\00742\00742.066002 Sequence Statement.wpd